CClinicalTrials.gg
Status unknownNCT05519995Updated Aug 29, 2022

Sensate II Utilization and Perceived Stress in Adults

An observational study in Stress Disorder and Stress, sponsored by BioSelf Technology. Status unknown at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-29.

Sponsored by BioSelf Technology · Observational

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
360
Ages
18 Years and older
Sex
All
01

Study summary

Sensate® is A commercially marketed (FCC #: 2AS9ESEN231) stress management wellness device (BioSelf Technology; London, UK). This non-invasive wellness device is one component of a cross-modal (acoustic and aural) sensory experience designed to help an individual experience relaxation following a 10 to 30-minute session. The wellness device is paired with an in-app software program that offers infrasonic vibrations that are proprietarily synced to music or soundscapes. The wellness device is recommended in blogs, and online news articles as a possible modality for positive stress management (Bergland, 2017; Woodhall, 2018; Woolton, 2018), and anecdotal evidence from social media influencers suggest a relaxing response (Garth, 2021; Knight, 2021; Patterson, 2020). Moreover, a 2021 survey response from consumers of Sensate suggests an improvement in stress response during the COVID-19 pandemic (McDoniel \& Chmelik, 2022). However, it is unknown to what extent, if any, the use of Sensate II correlated with validated measures of stress, affect, or sleep quality in adults.

Read the detailed description

This study aims to assess the possible relationship between Sensate II utilization (Frequency, Duration, \& Time) and perceived stress, affect, and sleep quality in adults.

  1. Is there a relationship between Sensate II utilization and perceived stress
  2. Is there a relationship between Sensate II utilization and postive \& negative affect
  3. Is there a relationship between Sensate II utilization and sleep quality. It is hypothesized that significant relationship existis between Sensate II utilization and perceived lower stress, higher postive affect, lower negative affect, and sleep quality.

References Bergland, C. (2017). Will stress-busting vagus nerve gadgetry be a game changer? Non-invasive vagus nerve stimulation reduces "fight-or-flight" stress responses. Psychology Today. http://www.psychologytoday.com/us/blog/the-athletes-way/201711/will-stress-busting-vagus-nerve-gadgetry-be-gamechanger

Garth, E. (2021). Review: Sensate stress and anxiety management. Longevity.Technology. http://longevity.technology/lifestyle/review-sensate/

Knight, S. (2021). Does the Sensate 2 do anything apart from vibrate your ribcage? http://www.makeuseof.com/sensate-review/

McDoniel, S., \& Chmelik, S. (2022). A non-invasive device for stress management. https://www.researchgate.net/project/A-Non-Invasive-Wellness- Device-for-Stress-Management

Patterson, B. (2020). Sensate Meditation Device Review. http://the-gadgeteer.com/2020/07/10/sensate-meditation-device-review/

Woodhall, V. (2018). Vagus nerve: The new key to stress relief and good health. The Times. https://www.thetimes.co.uk/article/vagus-nerve-the-new-keyto- stress-relief-and-good-health-b0778h20q

Woolton, C. (2018). Wellness: Fear of flight. https://www.vogue.co.uk/article/fear-of-flying-sensate-review

02

Conditions studied

  • Stress Disorder
  • Stress

Keywords

  • Stress
  • Vagus Nerve
  • Emotions
  • Sleep
03

In context

Stress Disorders, Traumatic

1,147 studies on the registry are indexed under Stress Disorders, Traumatic; 108 are open to participants now.

This study's planned enrollment of 360 is above the median of 140 across 177 observational studies indexed under Stress Disorders, Traumatic.

Browse Stress Disorders, Traumatic studies →

Lead sponsor

This is the only study on the registry with BioSelf Technology as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Adults users of Sensate

Inclusion criteria

Inclusion for this study will be adults (18+ years of age) who have been using the Sensate II device for stress management for a minimum of 30-days or one month.

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
360 participants (estimated)
Patient registry
No

Groups and cohorts

  • Sensate II Users

    Users will be adults (18+ years of age) who have been using the Sensate II device for stress management for a minimum of 30-days or 1-month

06

What researchers measure

Primary outcomes

  1. Perceived Stress

    Measure of perceived stress scale.

    Time frame: 1-month

  2. Postive Affect

    Measure of positive Affect

    Time frame: 1-month

  3. Negative Affect

    Measure of negative Affect

    Time frame: 1-month

  4. Sleep Quality

    Measure of sleep quality

    Time frame: 1-month

07

Study locations

1 of 1 sites recruiting
  • BioSelf Technology
    London, United Kingdom
    • Stefan Chmelik, MSc · Contact
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Perceived Stress Scale, Positive / Negative Affect, \& Discrete Emotions, Utilization of Sensate

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05519995
Lead sponsor
BioSelf Technology
Responsible party
Sponsor
First posted
Aug 29, 2022
Start date
Aug 20, 2022
Primary completion
Sep 15, 2022 (estimated)
Completion
Dec 1, 2022 (estimated)
Last update
Aug 29, 2022

Study contacts

Scott O McDoniel, PhD
Contact
scott.mcdoniel@gmail.com
720-295-1409
Scott O McDoniel, PhD
principal investigator · McDoniel Holdings, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion